For further information, visit ISAAA’s website at http://www.isaaa.org.
Biotech crops in the last 22 years of commercialization have brought immense economic benefits, health improvement and social gains which should be shared with the global community. Accurate information on the benefits and potentials of biotech crops will allow farmers and consumers to make informed-choice in what crops to grow and consume, respectively; policy makers and regulators to craft enabling biosafety guidelines for commercialization and adoption of biotech crops; and science communicators and the media to facilitate dissemination of the benefits and potentials of the technology. Read more
(June 26, 2018) – Today, the International Service for the Acquisition of Agri-biotech Applications (ISAAA) and PG Economics, Ltd. released new studies highlighting the continued social, environmental and economic benefits of the global adoption of biotechnology in agriculture. Read more
PRESS RELEASE, 19 May 2017: Biotech/GM corn production in the Philippines rebounds in 2016 as the country remains to be the top grower of biotech or genetically modified (GM) crops in Southeast Asia, and ranks as the twelfth biggest producer of such crops in the world, according to the latest report from the International Service for the Acquisition of Agri-biotech Applications (ISAAA). Read more
SEARCA, in collaboration with the International Service for the Acquisition of Agri-biotech Applications (ISAAA), is pleased to invite you and your colleagues to the following seminar at the SEARCA headquarters, UPLB Campus, Los Baños, Laguna:
Global Status of Commercialized Biotech/GM Crops in 2016
by Dr. Paul S. Teng
Chair of the Board, ISAAA and Senior Fellow, SEARCA
19 May 2017 (Friday), Drilon Hall, 3:00 p.m.
The SEARCA Agriculture & Development Seminar Series (ADSS) and its special seminars are open to the public. It is meant to encourage the presentation and discussion of development and research issues, as well as their implications for agricultural and rural development. Through the ADSS, SEARCA proactively contributes to having a vibrant scientific exchange within, and even beyond, the Los Baños Science Community.
The International Service for the Acquisition of Agri-biotech Applications (ISAAA) launched its 2016 report titled Global Status of Commercialized Biotech/GM Crops: 2016. Two launch events were held on May 4 and 5, 2017 in Beijing, China.
The media conference held on May 4, 2017 at China Wold Hotel was attended by some 40 journalists from Chinese and international news agencies. ISAAA Chair, Dr. Paul Teng, presented the highlights of the report. He stressed that the adoption of biotech crops increased to 185.1 million hectares in 2016 after the slight decline observed in 2015. ISAAA Senior Program Officer, Dr. Rhodora Aldemita, talked about the development and adoption of biotech crops in Asia.
The following day, a seminar was held on May 5, 2017 at the Chinese Academy of Sciences, which was attended by 120 scientists, members of the academe, and students. Drs. Paul Teng and Rhodora Aldemita presented the highlights of the ISAAA report. Mr. Zhang Xianfa from the Ag GMO Division of the Ministry of Agriculture discussed the status of Chinese biotech crops regulation and development. The participants signified their interest in the adoption of more biotech crops in the country to benefit not just the farmers and their families, but also the consumers.
The events were organized in cooperation with China Biotechnology Information Center, Chinese Academy of Agricultural Sciences, and the Chinese Biotechnology Society.
-Published by ISAAA. See original article link here.
This 2016 ISAAA Brief is an extension of the 20 Volumes of Annual Briefs (1996 to 2015) on global status of biotech/GM crops authored by Clive James,
Founder & Emeritus Chairman of ISAAA
The International Service for the Acquisition of Agri-biotech Applications publishes the Annual Global Review of Biotech Crops Commercialization or ISAAA Briefs. ISAAA Brief 52 is the 21st of the series which documents the latest information on the subject, global database on the adoption and distribution of biotech crops in 2016 as well as the accumulative data since 1996 (the first year of commercialization), country situations, trends in approval of biotech crops, and future prospects of the technology in the biotech crop growing countries and the world. ISAAA Brief is one of the most cited references in the field of modern agri-biotechnology due to its credibility and accuracy. Since the adoption of biotech crops in 1996, ISAAA has remained the single most prominent source of this information.
The year 2016 was momentous since for the first time, Nobel Laureates released a statement in support of biotechnology and condemning critics in their critical stance against the technology and Golden Rice. The UN Food and Agriculture Organization, International Food and Policy Research Institute, the G20 countries and other like-minded bodies, guided by 2030 Agenda for Sustainable Agriculture have committed to eradicate hunger and malnutrition in 15 years or less. More importantly, the US National Academies of Sciences, Engineering, and Medicine published a review of 900 researches on biotech crops since 1996 and found that genetically modified crops and conventionally-bred crops have no difference in terms of probable risks to human health and the environment. Biotech crops have now had an unblemished record of safe use and consumption for over 20 years. Future generations can benefit more from wide choices of biotech crops with improved traits for high yield and nutrition as well as safe for food use and environment.
• Biotech crop planting in 2016 resumes high adoption at 185.1 million hectares worldwide.
A year after the second decade of commercialization of biotech/GM crops in 2016, 26 countries grew 185.1 million hectares of biotech crops – an increase of 5.4 million hectares or 3% from 179.7 million hectares in 2015. Except for the 2015 adoption, this is the 20th series of increases every single year; and notably 12 of the 20 years were double-digit growth rates.
• Biotech crops provide more diverse offerings to consumers in 2016
Biotech crops have expanded beyond the big four (corn, soybean, cotton, and canola) to give more choices for many of the world’s consumers. These biotech crops include sugar beet, papaya, squash, eggplant, potatoes that are already in the market, as well as apples which will be in the market in 2017. Potato is the fourth important staple crop in the world and eggplant is the number one vegetable consumed in Asia. Non-bruising and non-browning apples and potatoes can contribute to the reduction of food waste. Additionally, research done by public sector institutions include crops such as rice, banana, potato, wheat, chickpea, pigeon pea, mustard and sugarcane at advanced stages of evaluation, and are likely to provide even more diverse offerings to consumers, especially those in developing countries.
• New biotech crops and traits in the pipeline for the benefit of farmers and consumers
It is noteworthy that new biotech crops and traits are being field tested to cater to farmers and consumers. These include among others, staple crops such as beta-carotene enriched Golden Rice being tested in the Philippines and Bangladesh; bunchy top virus resistant biotech banana in Uganda; Fusarium wilt resistant biotech banana and biotech wheat with disease resistance, drought tolerance, altered oil content and grain composition being field tested in Australia; high yield and biomass wheat in the United Kingdom; late blight resistant potato varieties Desiree and Victoria in Uganda and late blight and nematode resistant potato variety Maris Piper with less bruising and less acrylamide potato in the EU; insect resistant chickpea and pigeon pea, and biotech mustard which are staple vegetables and oil source, respectively, in India; drought tolerant sugarcane in India and Indonesia; and omega-3 enriched camelina in the EU.
• Biotech crops increased ~110-fold from 1996, the fastest adopted crop technology in the world; accumulated hectarage at 2.1 billion hectares
Global hectarage of biotech crops has increased ~110-fold from 1.7 million hectares in 1996 to 185.1 million hectares in 2016 – this makes biotech crops the fastest adopted crop technology in recent times. An accumulated 2.1 billion hectares or 5.3 billion acres was achieved in 21 years (1996-2016) of biotech crop commercialization.
• 26 countries, 19 developing and 7 industrial countries grew biotech crops
The 185.1 million hectares of biotech crops were grown by 26 countries, of which 19 were developing and 7 industrial countries. Developing countries grew 54% (99.6 million hectares) of the global biotech crop area compared to 46% (85.5 million hectares) for industrial countries.
• Biotech soybean reached 50% of global biotech crop hectarage
The four major biotech crops: soybean, maize, cotton, and canola, in decreasing area, were the most adopted biotech crops by 26 countries. The area planted to biotech soybean was the highest at 91.4 million hectares, which is 50% of the global hectarage of 185.1 million hectares for all biotech crops. Although the soybean area only showed a marginal decrease of 1% from 2015 (92.7 million hectares), the area is still substantial at 91.4 million hectares. Based on the global crop hectarage for individual crops, 78% of soybean, 64% of cotton, 26% of maize and 24% of canola were biotech in 2016.
• Stacked traits occupied 41% of the global hectarage, second to herbicide tolerance at 47%
Herbicide tolerance deployed in soybean, canola, maize, alfalfa, and cotton, has consistently been the dominant trait at 47% of the global hectarage. A declining trend on herbicide tolerant crops planted was observed with the rise of stacked traits (combined insect resistance, herbicide tolerance, and other traits). The area planted to herbicide tolerant crops was 86.5 million hectares in 2016, occupying 47% of the global biotech hectarage of 185.1 million hectares. On the other hand, area planted to stacked traits increased by 29% in 2016 at 75.4 million hectares from 58.4 million hectares in 2015. Stacked traits occupied 41% of the global biotech crop hectarage of 185.1 million hectares.
• Of the top five countries growing 91% of biotech crops, three are developing countries (Brazil, Argentina, and India) and two are industrial (USA and Canada).
USA leads biotech crop planting in 2016 at 72.9 million hectares, followed by Brazil (49.1 million hectares), Argentina (23.8 million hectares), Canada (11.6 million hectares) and India (10.8 million hectares) (Table 1, Figure 1) for a total of 168.2 million hectares, 91% of the global hectarage.
USA continued to be the leader in the global commercialization of biotech crops since 1996. In 2016, 72.9 or ~73 million hectares were planted to major biotech crops: maize (35.05 million hectares), soybean (31.84 million hectares), cotton (3.70 million hectares), some areas of biotech crops: alfalfa (1.23 million hectares), canola (0.62 million hectares), and sugar beet (0.47 million hectares) and small areas of virus resistant papaya and squash (1,000 hectares each), and non-browning Innate™ potatoes (2,500 hectares). The USDA estimates indicate that the percentage adoption of the three principal biotech crops were at, or close to optimal adoption: soybean at 94% (same as 2015), maize 92% (same as 2015), and cotton 93% (lower by 1% in 2015) (USDA, NASS, 2016), for an average of 93%. The 2016 biotech crop area in the USA of ~73 million hectares is 39% of the global biotech area and 3% higher than the 2015 planting of 70.9 million hectares. The immediate increase of biotech/GM crop planted area in the USA in 2016 indicates that the 2015 slight decrease attributed to low commodity prices of maize and cotton was only temporary. Resumption of global prices and the active trade with countries for livestock feeds, food processing, and biofuel needs in 2016 put the US biotech crop adoption back on track with 3% increase from 2015.
Brazil retained its #2 world ranking after the US, with 49.1 million hectares of biotech crops planted, representing 27% of the global hectarage of 185.1 million hectares. Brazil’s total biotech crop hectarage of ~49.14 million hectares is an increase of 11%, from 2015 (44.2 million hectares), or 4.9 million hectares. This 4.9 million hectare increase was by far the highest increase in any country worldwide in 2016 making Brazil the engine of growth in biotech crops worldwide. Biotech crops planted include: ~32.7 million hectares biotech soybean; 15.7 million hectares of biotech maize (summer and winter maize); and ~0.8 million hectares of biotech cotton. The total planted area of these three crops in Brazil was estimated at 52.6 million hectares of which 49.14 million hectares or 93.4% was biotech. The adoption rate of 93.4% is a 2.7% increase in adoption compared to 2015 (90.7%). Similar to the U.S., adoption rates of the three major biotech crops are almost optimal at an average of 93.4%. IR/HT soybean Intacta™ has gained popularity among the farmers because of the savings in pesticide and the no-till technology, thus, the increased hectarages. The need for continuous and steady supply of maize for pork and livestock industry in the country may push farmers to plant more maize in 2017.
Argentina maintained its ranking as the third largest producer of biotech crops in the world in 2016, after the USA and Brazil, occupying 13% of global hectarage. The country planted 23.82 million hectares, 0.67 million hectares less than the 24.49 million hectares in 2015. Biotech crops in the country was comprised of 18.7 million hectares of biotech soybean, an all time high of 4.74 million hectares of biotech maize and a reduced cotton biotech area of 0.38 million hectares. The country had a slight decline in hectarages of biotech crops due largely to soybean and minimally with cotton due to global low cotton prices. The adverse weather condition was not conducive to wheat planting and affected the 2nd soybean planting after wheat. On the other hand, increased maize planting was mainly due to favorable weather conditions. With almost maximum adoption of biotech crops in Argentina of 97%, expansion of biotech crop commercialization can be achieved using new crops and traits.
Canada is fourth in world ranking of biotech crops, with an area of 11.55 million hectares, a 5% increase from 2015 of 10.95 million hectares, with an average adoption rate of 93%, similar to 2015. The four biotech crops grown in Canada in 2016 were canola (7.53 million hectares), soybean (2.08 million), maize (1.49 million), sugar beet (8,000 hectares with 100% adoption) and for the first time low lignin alfalfa (809 hectares). Total planting of these crops also increased by 5% from 11.74 million hectares (2015) to 12.38 million hectares. The country increased biotech crop planting following increases in total area of canola, soybean, and maize. Canola Council of Canada actively pursues its Strategic Plan of producing 26 MMT canola by 2025 through yield improvement technologies. Increase in soybean area is due to its profitability and high oilseed prices. For maize, increased gasoline and ethanol consumption due to lower gas prices provided incentive for maize planting.
India had a slight decrease (7%) in biotech cotton planting brought by a small reduction in the total cotton area (8%) in the 10 states of India. Adoption however increased from 95% to 96% indicative of acceptance by as much as 7.2 million farmers benefiting from the technology. Biosafety regulations in the country have been streamlined with revised guidelines on the monitoring of confined field trials of biotech crops. Biotech mustard expressing the barnase-barstar gene is under final review including public comments for environmental release in 2017. Mustard production and yields have remained stagnant for the past 20 years and the future introduction of the biotech mustard can potentially increase yield by as much as 25%, revive the mustard industry and be competitive with canola. Insect resistant chickpea and pigeon pea were approved for field trials by the government regulatory agency in 2016. India retained the title as the number one cotton-producing country in the world with cotton production surpassing 35 million bales despite the slowed down global cotton market.
• Ten countries in Latin America grew ~80 million hectares of biotech crops
Except for Chile and Costa Rica which continuously plant biotech crops for export, biotech crop countries in Latin America grew biotech crops for food, feed and processing. Brazil obtained the highest increase of 11% or 4.9 million hectares of biotech crops in 2016 and occupied 27% of the global biotech crop area. Intacta™ has gained popularity among farmers because of savings in pesticide and the no-till technology. Adoption rates of the three major biotech crops were almost optimum at an average of 93.4% in Brazil and Argentina. Total soybean and biotech plantings in Argentina and Bolivia were affected by severe drought. Moreover, in Paraguay, marginal decrease in soybean area was due to competition with maize planting to cater for the increasing demand of the expanding pork industry in the country. In Mexico, reduced soybean planting was due to conflicts resulting from negative propaganda for biotech crops. Biotech soybean and maize decreased in Uruguay due to lowered prices, higher production costs and positive policy developments for grain and soybean sector in Argentina. Lowered cotton prices also negatively affected Argentina, Mexico, and Colombia.
The possible expansion in the pork and livestock industry in Brazil may push farmers to plant more maize in 2017. New products waiting to be commercialized which are expected to impact the Brazilian economy are the biotech eucalyptus and virus resistant bean. In Argentina, the development of drought tolerant soybean which is now in testing stage will allow utilization of marginal areas affected by drought. Also, adoption of virus resistant potato will be beneficial to farmers in increasing yield and reduction of production cost. The area expansion in Paraguay and Colombia for total maize was due to the increasing expansion of the pork industry. This is likely to continue in the next few years with maize prices relatively higher due to demand from Brazil and Chile. Biotech maize adoption may also increase consequently. Countries affected by low global cotton prices may rebound back as soon as prices become stable, similar to maize which suffered low prices in the last two years. New biotech crops and traits that can withstand drought and other stress will be a welcome respite from the losses of the past years.
• Eight countries in Asia and the Pacific grew ~18.6 million hectares of biotech crops
Biotech crops planted in the 8 biotech crop countries of Asia and the Pacific ranged from fiber (cotton), feed (maize and canola) and food (maize and eggplant). Adoption of these biotech crops varied in 2016: India and China’s biotech cotton planting were extremely affected by low global cotton prices, while Pakistan and Myanmar maintained their biotech cotton area. The area planted to biotech maize in the Philippines and Vietnam increased due to high demand for livestock and poultry feeds, as well as favorable weather conditions. In Australia, favorable weather conditions after two years of drought permitted increased planting of biotech cotton and canola. In addition, farmers were provided BollgardIII/RR®Flex cotton for extreme insect pest protection with herbicide tolerance. Bangladesh increased its Bt eggplant planting to 700 hectares and more brinjal varieties with Bt gene are being field tested for future commercialization.
There are still huge potential biotech maize areas in China, Vietnam, Pakistan and the Philippines, as well as biotech cotton for Vietnam, Bangladesh and the Philippines. In China, food and manufacturing industry considered potato as the fourth staple with renewed interest on its research, development and production. The upcoming biotech potatoes which are non-bruising, low acrylamide, lowered reducing sugar and late blight resistant, as well as beta-carotene enriched Golden Rice will help address malnutrition and hunger in Asia and the Pacific.
• Four countries in the European Union continued to plant biotech maize at more than 136,000 hectares
Four countries in the EU (28) continued to plant biotech maize (IR maize event MON 810). In 2016, they were Spain with 129,081 hectares, Portugal (7,069 hectares), Slovakia (138 hectares) and Czechia (75 hectares) for a total of 136,363 hectares. Thus, a significant difference of 19,493 hectares or 17% increase from 116,870 in 2015 was achieved. The more than 95% of the total biotech maize in the EU was planted in Spain. In Spain and Slovakia, increases in biotech maize planting were due to favorable farmers’ decision to plant insect resistant maize because of the devastating European corn borer infestation. In Portugal, in addition to the low market price of maize, drought spell affected the highest maize producing state, Alentejo. This resulted to a decline in total maize area and consequently the biotech maize area. In Czechia however, the continuing decline in biotech crop planting was due to the inconvenience of stringent reporting requirements for IR maize resulting in less incentive for farmers and all stakeholders seeking to capture the benefits offered by IR maize. This matter also affected Romania, which, similar to the other countries have opted to grow GM crops after the EU directive was issued in 2015. Thus, for 2016, there was no biotech maize planting in Romania.
Possible expansion of biotech crops in these countries includes the approval of new crops and traits that will address the recurring problem of corn borer infestation such as the various IR/HT maize technologies. In addition, drought tolerant maize available in the US and a product similar to the biotech maize with drought and insect resistant trait of the WEMA Project will benefit farmers in Portugal.
• South Africa and Sudan had increased planting of biotech crops
By 2016, at least four countries had in the past placed a GM crop in the market – Burkina Faso, Egypt, South Africa, and Sudan. However, due to a temporary setback in Burkina Faso and Egypt, only South Africa and Sudan planted biotech crops at 2.8 million hectares. South Africa is one of the top ten countries planting more than 1 million hectares in 2016 and continued to lead the adoption of biotech crops in the African continent. Biotech maize, soybean and cotton area increased to 2.66 million hectares in 2016, a 16% increase from the 2.29 million hectares in 2015.
A new wave of acceptance is emerging in the continent. Three countries: Kenya, Malawi and Nigeria transitioned from research to granting environmental release approvals, while six others – Burkina Faso, Ethiopia, Ghana, Nigeria, Swaziland and Uganda made significant progress in moving towards completion of multi-location trials in readiness for considering commercial approval. Three of these crops – banana, cowpea and sorghum are new and primarily for food security. It is noteworthy that under the Water Efficient Maize for Africa (WEMA), Tanzania planted its first ever confined field trial of drought tolerant maize while Mozambique granted its first ever approval for a confined field trial of a stacked trait, an insect reistant and drought tolerant maize.
Biotech crops were planted in small scale as early as 1994 and large scale plantings were recorded in 1996. From 1994 to 2016, a total of 40 countries (39 + EU – 28) have issued regulatory approvals to genetically modified crops for consumption either as food and/or feed as well as for environmental release. From these countries, 3,768 approvals have been issued by regulatory authorities across 26 GM crops (not including those for carnation, rose and petunia) and 392 GM events. Of these approvals, 1,777 are for food use (direct use or for processing), 1,238 are for feed use (direct use or for processing) and 753 are for environmental release or cultivation (Table 2). Maize still has the most number of approved events (218 in 29 countries), followed by cotton (58 events in 22 countries), potato (47 events in 11 countries), canola (38 events in 14 countries), and soybean (35 events in 28 countries).
The herbicide tolerant maize event NK603 (54 approvals in 26 countries + EU-28) still has the most number of approvals. It is followed by herbicide tolerant soybean GTS 40-3-2 (53 approvals in 27 countries + EU-28), insect resistant maize MON810 (52 approvals in 26 countries + EU-28), insect resistant maize Bt11 (50 approvals in 24 countries + EU-28), insect resistant maize TC1507 (50 approvals in 24 countries + EU-28), herbicide tolerant maize GA21 (49 approvals in 23 countries + EU-28), insect resistant maize MON89034 (48 approvals in 24 countries + EU-28), herbicide tolerant soybean A2704-12 (42 approvals in 23 countries + EU-28), insect resistant maize MON88017 (41 approvals in 22 countries + EU-28), insect resistant cotton MON531 (41 approval in 21 countries + EU-28), herbicide tolerant maize T25 (40 approvals in 20 countries + EU-28) and insect resistant maize MIR162 (40 approvals in 21 countries + EU-28).
In 2016, the global market value of biotech crops, estimated by Cropnosis was US$15.8 billion (up by 3% from US$15.3 billion in 2015); this represents 22% of the US$73.5 billion global crop protection market in 2016, and 35% of the US$45 billion global commercial seed market. The estimated global farm-gate revenues of the harvested commercial “end product” (the biotech grain and other harvested products) are more than ten times greater than the value of the biotech seed alone.
Biotech crops contributed to food security, sustainability and climate change by:
• increasing crop productivity 574 million tons valued at US$167.8 billion in 1996-2015; and 75 million tons valued at US$15.4 billion in 2015 alone;
• conserving biodiversity in 1996 to 2015 by saving 174 million hectares, and 19.4 million hectares in 2015 alone;
• providing a better environment
– by saving 620 million kg. active ingredient (a. i.) of pesticides in 1996-2015, and by 37.4 million kg in 2015 alone;
– by reducing pesticide applications, saving 8.1% in 1996-2015, and by 6.1% in 2015 alone;
– by reducing EIQ (Environmental Impact Quotient) by 19% in 1996-2015, and by 18.4% in 2015 alone
• reducing CO2 emissions in 2015 by 26.7 billion kg, equivalent to taking 11.9 million cars off the road for one year; and
• helped alleviate poverty by helping 18 million small farmers, and their families totaling >65 million people, who are some of the poorest people in the world (Brookes and Barfoot, 2017, Forthcoming).
Thus, biotech crops can contribute to a “sustainable intensification” strategy favored by many science academies worldwide, which allows productivity/production to be increased only on the current 1.5 billion hectares of global crop land, thereby saving forests and biodiversity. Biotech crops are essential but are not a panacea and adherence to good farming practices, such as rotations and resistance management, are a must for biotech crops as they are for conventional crops.
Onerous regulation for transgenic crops remains the principal constraint to adoption, which is particularly important for many developing countries, denied the opportunity of using biotech crops to address food, feed, and fiber security. Opponents of GM crops are against science-based regulation and are demanding onerous regulation that is denying poor farmers in the developing countries, as well as Europe’s access to the technologies. All these challenges are faced by farmers and technology developers despite the overwhelming evidence in support of the safe use of these technologies. By using these technologies, small poor farmers will be able to survive and contribute to the doubling of food production to meet the needs of a growing population which will reach over 11 billion in 2100.
As biotech crops enter the third decade of planting/commercialization, game changing innovations are projected to revolutionize development of new biotech crops and traits. Firstly, the increasing adoption and appreciation by farmers of stacked traits; secondly, the advent of biotech crops and traits that not only cater to farmers agricultural needs but more so the preference and nutritional needs of consumers; and thirdly, the heightened utilization of innovative tools of gene discovery and their subsequent use in crop improvement and varietal development.
The first generation of biotech crops targeted input traits of herbicide tolerance, insect resistance and virus resistance where farmers and food producers benefited economic gains of 574 million tons valued at US$167.8 billion in 1996-2015. These benefits also provided accessible food and nutrition for the 7.4 billion global population. The second generation biotech crops include stacks of these traits, as well as drought tolerance – one of the problems related to climate change. Adoption of IR/HT soybean (Intacta™) and corn rootworm stacks for maize have been phenomenal with an economic benefit of US$2.4 billion in 2013-2015 and US$12.6 billion in 2003 to 2015, respectively (Brookes and Barfoot, 2017 Forthcoming).
Output traits for improved quality and composition were the traits of the third generation biotech crops geared towards consumer preference and nutrition. These include the various health-improving products of soybean for humans and animals (omega-3 fatty acids, high oleic acid, low phytate, and high stearic acid), modified starch/sugar (potato), low-lignin (alfalfa), non-browning potatoes which are already available; non-browning apples projected to be available in the US market in 2017; as well as beta-carotene and ferritin in major staple crops which are already in the advanced stages of development. It is noteworthy that Innate™ potato series have been commercialized successfully in the USA, with 2,500 hectares of potatoes and 70,000 non-browning apple trees (~81 hectares). Acceptance of these two biotech crops can contribute in the reduction of food waste due to browning and easy spoilage of products.
Innovative molecular biology tools are continuously being developed and tapped to discover new genes that would make food available, accessible and nutritious. Biotech products which are already in field testing and maybe released in the next few years reflect the increasing trends for various inputs and output traits for farmers and consumers. Staple crops such as rice, banana, potato, wheat, ryegrass, Indian mustard, chickpea, pigeon pea and sugarcane, among others were improved to contain new traits for insect and disease resistance, drought and stress tolerance, improved nutritional content, and yield and biomass among others.
The encouraging outlook is that technology, in conjunction with conducive policies can double food production. However, the doubling of food production cannot be realized by society unless it ensures that regulation of GM crops is science/evidence-based, fit for purpose, and to the extent possible harmonized globally. Failure by global society to ensure timely and appropriate regulation on food production will have dire consequences. On the one hand, the world will suffer because of inadequate food supplies, while on the other hand, the power of science and technology to produce a safe, adequate and assured supply of food for all mankind will be rejected because of the dominant ideological voices of the opponents of the new biotechnologies.
In 2016, global hectarage of biotech crops increased from 179.7 million hectares to 185.1 million hectares, a 3% increase equivalent to 5.4 million hectares. Predictions made by James, C. (2015) that the slight decline in biotech crop area in 2015 due to the low global commodity price would immediately reverse once crop prices revert to higher levels were realized – this is contrary to propaganda by critics that biotech crops are failing the farmers. Fluctuations in biotech crop hectarage of this order (both increases and decreases) are influenced by several factors. In 2016, these factors were: acceptance and commercialization of new products in the USA, Brazil and Australia; increasing demand for pork and livestock feeds in Brazil; needs for livestock and poultry feeds in Vietnam; favorable weather conditions and improved market price for maize in the Philippines and Honduras; need to address corn borer infestation in Spain and Slovakia; government’s strategic plan to harness biotechnology and improve economy in Canada; the lifting of the GM ban in West Australia; and consumers demand for more of the clean and healthy brinjal in Bangladesh. Biotech crop hectarage in Myanmar and Pakistan did not change, as in some smaller countries.
A few countries had decreased biotech crop planting due to global low cotton prices such as in Argentina, Uruguay and Mexico, and high cotton reserve stocks particularly in China and low cotton price in India; low profitability in soybean and competition with maize in Paraguay and Uruguay; environmental stress (drought/submergence) in soybean plantings in South Africa, Argentina and Bolivia; negative biotech perception in China as well as onerous reporting requirements in Czech Republic. Lastly, onerous requirements made farmers in Romania stop planting biotech crops in 2016.
Finally, biotech crops are here to stay and will continue benefiting the burgeoning population with new biotech crops and traits to cater to the needs of farmers and consumers alike. However, even after 21 years of successful commercialization of biotech crops, some challenges remain including:
• First, the regulatory barriers that limit scientific innovation and restricts technology development that would have benefited farmers and consumers.
• Second, the growing trade disruptions brought by asynchronous approvals and thresholds on low level presence in GM crop trading countries. Following the Cartagena Protocol on Biosafety, countries allow entry of only approved biotech events, and a threshold for unapproved events. Some countries have stringent or long process of approvals that cause problems if imported products contain unapproved events, especially in a stacked event. The report and analysis by the Council for Agricultural Science and Technology (CAST, 2016) on the Impact of asynchronous approvals for biotech crops on agricultural sustainability, trade and innovation indicate that there are large volumes of trade worth billions of dollars at risk. A thorough research is needed to evaluate the global cost of asynchronous approvals and low level presence (LLP), the impacts of asynchrony on innovation and crop improvements, and the decision-making process of biotech developers, in both the public and private sectors. Timely research and possibly, an international dialogue on trade would inform policymaking and improve the design of policy instruments.
• Third, the need for continuous dialogue among all stakeholders for the expeditious understanding and appreciation of biotechnology, emphasizing benefits and safety. Innovative communication modalities using social media and other forms of venues should be tapped and utilized effectively and immediately.
Overcoming these challenges is a daunting task that requires a cooperative partnership among the North and the South, East and West, and public and private sector. Only through partnerships can we be assured that nutritious and sufficient food will be readily available on the table, stable supply of feed for our poultry and livestock, and accessible clothing and shelter for everyone.
Dr. Clive James, founder and emeritus chair of ISAAA, has painstakingly authored the 20 annual reports ensuring the ISAAA Brief to be the most credible source of information on biotech crops in the last two decades. He has been a great advocate of the technology and biotech products following the footsteps of his great mentor and colleague the late Nobel Peace Laureate Norman Borlaug, who was also the founding patron of ISAAA. The 2016 ISAAA Brief continues this tradition of providing an up-to-date report on biotech products through information gathered from an expansive global network of biotechnology information centers and other partners.
For more information, visit ISAAA’s page at http://www.isaaa.org.
Beijing (May 4, 2017) – Today, the International Service for the Acquisition of Agri-biotech Applications (ISAAA) released its annual report showcasing the 110-fold increase in adoption rate of biotech crops globally in just 21 years of commercialization – growing from 1.7 million hectares in 1996 to 185.1 million hectares in 2016. ISAAA’s report, “Global Status of Commercialized Biotech/GM Crops: 2016,” continues to demonstrate the long-standing benefits of biotech crops for farmers in developing and industrialized countries, as well as consumer benefits of recently approved and commercialized varieties.
“Biotech crops have become a vital agricultural resource for farmers around the world because of the immense benefits for improved productivity and profitability, as well as conservation efforts,” said ISAAA Chair of the Board, Paul S. Teng. “With the commercial approvals and plantings of new varieties of biotech potatoes and apples, consumers will begin to enjoy direct benefits of biotechnology with produce that is not likely to spoil or be damaged, which in turn has the potential to substantially reduce food waste and consumer grocery costs.”
Examining other benefits of biotechnology, ISAAA reports that the adoption of biotech crops has reduced CO2 emissions equal to removing approximately 12 million cars from the road annually in recent years; conserved biodiversity by removing 19.4 million hectares of land from agriculture in 2015; and decreased the environmental impact with a 19% reduction in herbicide and insecticide use.1 Additionally, in developing countries, planting biotech crops has helped alleviate hunger by increasing the incomes for 18 million small farmers and their families, bringing improved financial stability to more than 65 million people.
“Biotechnology is one of the tools necessary in helping farmers grow more food on less land,” explained ISAAA Global Coordinator Randy Hautea. “However, the promises of biotech crops can only be unlocked if farmers are able to buy and plant these crops, following a scientific approach to regulatory reviews and approvals.”
As more varieties of biotech crops are approved and commercialized for use by farmers, ISAAA expects to see adoption rates continue to climb and to benefit farmers in developing countries. For example, among African nations where regulatory processes have traditionally created barriers to biotech crop adoption rates, advances are being realized. In 2016, South Africa and Sudan increased the planting of biotech maize, soybean and cotton to 2.66 million hectares from 2.29 million hectares in 2015. Elsewhere on the continent, a new wave of acceptance is emerging as Kenya, Malawi, Nigeria, Ethiopia, Ghana, Nigeria, Swaziland and Uganda make advances in regulatory review and commercial approvals for a variety of biotech crops.
“Even with a long history of regulatory barriers, African farmers continue to adopt biotech crops because of the value they are realizing from the stability and productivity of biotech varieties,” said Hautea. “As more countries move forward with regulatory reviews for crops such as bananas, cowpeas and sorghum, we believe biotech crop plantings will continue to grow in Africa and elsewhere.”
Also in 2016, Brazil increased biotech area of maize, soybean, cotton and canola by a remarkable 11% – maintaining its ranking as the second largest producer of biotech crops after the United States. In Brazil, biotech soybeans account for 32.7 million hectares of the 91.4 million hectares grown worldwide.
For 2016, ISAAA also reports that there were improvements in the commercialization and plantings of biotech fruits and vegetables with direct consumer benefits. These included the commercial approvals of the Innate™ Russet Burbank Gen 2 potatoes that were approved by the U.S. Food and Drug Administration for sale in the United States and the Simplot Gen 1 White Russet™ brand potatoes that were approved by Health Canada for fresh market sale in Canada. These biotech potato varieties have lower levels of asparagine, which reduces the creation of acrylamide during high-heat cooking. Additionally, the first commercially saleable quantities of Arctic® Apples were harvested in 2016, stored over the winter and are projected to be sold in U.S. grocery stores in 2017.
Additional highlights from ISAAA’s 2016 report include:
For more information or the executive summary of the report, visit www.isaaa.org.
1Brookes and Barfoot, 2017, Forthcoming
For more information, visit ISAAA’s page at http://www.isaaa.org.
This Brief focuses on the 20th Anniversary of the global commercialization of biotech crops (1996 to 2015) and biotech crop highlights in 2015. The author of this Brief, Dr. Clive James, has dedicated this Brief to his mentor and colleague, the late Nobel Peace Laureate Norman Borlaug, who was the founding patron of ISAAA. Borlaug was also the greatest advocate for biotechnology/GM crops, credited with saving 1 billion poor people from hunger during the 1960s green revolution that he created and pioneered.
20th anniversary (1996-2015) of the commercialization of biotech crops
2015 marked the 20th anniversary (1996-2015) of the commercialization of biotech crops, also known as genetically modified (GM) or transgenic crops, now more often called “biotech crops”, as referred to in this Brief. An unprecedented cumulative hectarage of 2 billion hectares of biotech crops, equivalent to twice the total land mass of China (956 million hectares) or the United States (937 million hectares), were successfully cultivated globally in the 20-year period 1996 to 2015; farmer benefits for the period 1996 to 2015 were estimated at over US$150 billion. The 2.0 billion accumulated hectares comprise 1.0 billion hectares of biotech soybean, 0.6 billion hectares of biotech maize, 0.3 billion hectares of biotech cotton and 0.1 billion hectares of biotech canola.
The experience of the first 20 years of commercialization, 1996 to 2015, has confirmed that the early promise of crop biotechnology has been fulfilled. Biotech crops have delivered substantial agronomic, environmental, economic, health and social benefits to farmers and, increasingly, to society at large. The rapid adoption of biotech crops, during the initial 20 years of commercialization, 1996 to 2015, reflects the substantial multiple benefits realized by both large and small farmers in industrial and developing countries, which have grown biotech crops commercially.
Global Status of biotech crops in 2015
In general, the status of biotech crops in 2015 was variable with several countries, led by Brazil with increasing hectarage, others led by the US with decreasing hectarage, and the balance of countries registering no or negligible year-to-year change, which was relatively low in 2015 and detailed in Table 1 and Figure 1.
Progress with adoption of biotech crops during the first 20 years
Following a remarkable run of 19 years of consecutive yearly growth from 1996 to 2014, the annual global hectarage of biotech crops peaked at 181.5 million in 2014, (see graph on cover page) compared with 179.7 million hectares in 2015; this change is equivalent to a net marginal year-to-year change of minus 1% between 2014 and 2015. Annual fluctuations in biotech crop hectarage (both increases and decreases) are influenced by several factors. In 2015, a principal factor leading to decreased biotech hectarage in some countries was decreased total crop plantings; for example, for maize it was minus 4% and for cotton minus 5%, driven by low prices, with some farmers switching from maize, cotton and canola to a more easily managed crop such as biotech soybean, and also to other less demanding crops like pulses, sunflower, and sorghum. Year-to-year biotech crop hectarage decreases, driven by low prices in 2015, are likely to reverse when crop prices revert to higher levels in the future.
Biotech crops are the fastest adopted crop technology in the world.
The global hectarage of biotech crops has increased 100-fold from 1.7 million hectares in 1996 to 179.7 million hectares in 2015 by up to 17 to 18 million farmers – this makes biotech crops the fastest adopted crop technology in recent times. This impressive adoption rate speaks for itself, in terms of its sustainability, resilience and the significant benefits it delivers to both small and large farmers as well as consumers.
Major developments in the US in 2015
Overall, significant progress was made on many fronts in the US in 2015 ranging from: new approvals; new commercialized biotech crops: first time approval of a GM animal food product for human consumption; widespread use of breakthrough new and powerful genome editing technology, named CRISPR; and some success on labeling.
For GM crop products, Innate™ generation 1, an improved multi-trait potato, developed by Simplot, was first commercialized on 160 hectares in 2015; an improved version, Innate™ 2 was approved in 2015, and has added resistance to the fungal disease, potato late blight, the cause of the Irish famine of 1845, when 1 million people died of hunger. Remarkably, it is still the most important disease of potatoes 150 years after the famine, with annual global losses of US$7.5 billion. Another global first was the commercialization of the first non-transgenic genome-edited crop, SU Canola™, developed by Cibus and grown on 4,000 hectares. Two varieties of Arctic® apples, with less bruising and less browning when sliced were approved for planting in the USA and Canada, with 6 hectares planted in the USA alone in 2015. The first delivery to consumers is planned for next year. The company that developed Arctic® apple, Okanagan Specialty Fruits, from Canada, is applying the same technology to other perishable fruits including peaches, pears and cherries. Okanagan Specialty Fruits was acquired by Intrexon, a US-based synthetic biology company, in 2015. A low lignin alfalfa event, KK179 (HarvXtra™) with higher digestibility and yield (alfalfa is #1 forage crop in the world) was already approved in November 2014 and is a candidate for commercialization in the US in 2016. Hectarage of biotech DroughtGard™ tolerant maize, first planted in the US in 2013, soared more than 15-fold from 50,000 hectares in 2013 to 275,000 hectares in 2014 and 810,000 hectares in 2015 reflecting high farmer acceptance. In December 2015, Dow and DuPont agreed to merge to form DowDuPont, with a view to splitting the new company into three companies focusing on Agriculture, Materials and Specialty Products.
For GM animals, after 20 years of review, in a landmark decision in November 2015, the FDA approved the first GM animal for commercial food production and human consumption – a faster growing GM salmon, which is expected to enter the food chain in the US before 2018; Atlantic salmon normally takes three years to harvest in fish farms, compared with only 18 months, or half the time, for GM salmon. The GM AquAdvantage salmon was developed by AquaBounty Technologies, which was acquired by the US company Intrexon in 2015. FDA approved a new GM chicken whose eggs will be used to treat a rare but fatal human disease called lysosomal acid lipase deficiency.
The award-winning CRISPR genome editing technology was selected by Science magazine as the breakthrough technology of 2015. It is being used in many laboratories to develop improved crops and animals. For example, improved soybeans and maize are already being evaluated in greenhouses and, subject to regulation, approval could be commercialized as early as five years from now. Pigs are being developed that are resistant to a deadly viral disease which costs the US pork industry US$600 million a year.
On labeling, whereas a herculean costly effort has been made by both proponents and opponents of GM crops, with mixed results, significant success was achieved by proponents in 2015. Ballots that would require state level labeling in Oregon and Colorado failed in 2014 and similarly ballots in 2015 in California and Washington failed. Perhaps, more importantly, a bill was passed in the House of Representatives in July 2015 that would pre-empt state and local non-GM laws; a similar bill is slated for an imminent hearing in the Senate. In November 2015, FDA rejected a “citizen petition” to require mandatory labelling of GM products. Finally, the food company Chipotle, after announcing that it would eliminate GM products from its menu, and focus solely on non-GM vegetable products sourced locally, is now re-centralizing its vegetable supply after up to 300 people in the US claim they have suffered sickness after consuming Chipotle non-GM locally sourced vegetables.
The top 5 countries planting biotech crops
The US continued to be the lead country with 70.9 million hectares (39% of global) with over 90% adoption for the principal crops of maize (92% adoption), soybean (94%), and cotton (94%).
Brazil, the second largest grower globally with 44.2 million hectares (reached 25% of global, for the first time in 2015), resumed its important role as the engine of biotech crop growth globally with 2 million hectares more in 2015 than 2014; this compares to minus 2.2 million hectares for the US. This decrease in the US is mainly due to a temporary reduction in total plantings of maize, cotton and canola which are expected to recover when prices of these crops strengthen and total hectarage increases. Notably, Brazil planted the stacked HT/IR soybean on a record 11.9 million hectares (up from 5.2 in 2014) in its third year after the launch. Argentina with 24.5 million hectares retained third place, and was up modestly from 24.3 million hectares in 2014. India ranked fourth, had 11.6 million hectares of Bt cotton (same as 2014), and a resilient 95% adoption rate. Canada was fifth at 11.0 million hectares, with 0.4 million hectares less total canola grown in 2015, but with a continued high rate of biotech adoption at 93%. In 2015, each of the top 5 countries planted more than 10 million hectares providing a broad, solid foundation for future sustained growth.
Up to 28 countries/annum grew biotech crops, in the period 1996 to 2015; Vietnam grew a biotech crop for the first time in 2015.
A global total of 17 to 18 million farmers, ~90% of which were small farmers, planted biotech crops in 28 countries in 2015 (Table 1 and Figure 1), 20 were developing and only 8 were industrial countries. The 28 countries include Vietnam which commercialized stacked biotech maize in 2015 for the first time. Cuba, which has planted biotech maize for the last two years will resume planting of biotech maize in two years’ time when their improved maize hybrids are ready for deployment.
Of the top ten biotech crop countries, listed by hectarage, 8 were developing.
Each of the top 10 countries, of which 8 were developing, grew more than 1 million hectares providing a broad-based worldwide foundation for continued and diversified growth in the future. More than half the world’s population, ~60% or ~4 billion people, live in the 28 countries which planted biotech crops in 2015.
Bangladesh, one of the smaller and poorest countries in the world, is an exemplary model of the importance of political will in the adoption of biotech crops.
Bangladesh, a small poor country with 150 million people, doubled the commercial hectarage of the prized vegetable Bt brinjal/eggplant; it was grown by 250 small farmers on 25 hectares in 2015 compared with 120 farmers on 12 hectares in 2014. Importantly, seed is now being multiplied to meet the growing needs of substantially more farmers in 2016. Success with Bt brinjal has led Bangladesh to prioritize the field testing of a new late blight resistant potato (an important crop occupying ~0.5 million hectares in Bangladesh) which could be approved as early as 2017; potato is the fourth most important food staple globally and can contribute to food security in countries like China (6 million hectares of potato), India (2 million) and the EU (~2 million). Given the importance of the large cotton/textile industry in Bangladesh, Bt cotton is being evaluated in field trials as well as Golden Rice, which could address the prevalent Vitamin A deficiency in the country. This feat of promoting home-grown biotech crops through public/private partnerships, PPP, is very effective but could not have been achieved without strong Government support and political will, particularly from the Minister of Agriculture, the Honorable Matia Chowdhury – the experience of Bangladesh is exemplary for small poor countries.
Up to ~18 million farmers benefit from biotech crops in the 20 year period 1996 to 2015 – ~90% were small resource-poor farmers.
In the period 1996 to 2015, up to approximately 18 million farmers, grew biotech crops annually – remarkably, about 90%, or 16.5 million, were risk-averse small, poor farmers in developing countries. The latest economic data available for the period 1996 to 2014 indicates that farmers in China gained US$17.5 billion and in India US$18.3 billion. In addition to economic gains, farmers benefited enormously from at least a 50% reduction in the number of insecticide applications, thereby reducing farmer exposure to insecticides, and importantly contributed to a more sustainable environment and better quality of life.
For the fourth consecutive year, developing countries planted more biotech crops than industrial countries in 2015.
In 2015, Latin American, Asian and African farmers collectively grew 97.1 million hectares or 54% of the global 179.7 million biotech hectares (versus 53% in 2014) compared with industrial countries at 82.6 million hectares or 46% (versus 47% in 2014), equivalent to a gap of 14.5 million hectares in favor of developing countries. The higher hectarage in developing countries is contrary to the prediction of critics who, prior to the commercialization of the technology in 1996, prematurely declared that biotech crops were only for industrial countries and would never be accepted and adopted by developing countries, particularly small poor farmers.
During the period 1996-2014, total cumulative economic benefits were US$150 billion: industrial countries at US$74.1 billion compared to US$76.2 billion generated by developing countries. In 2014, developing countries had 46.5% equivalent to US$8.3 billion of the total US$17.8 billion gain, with industrial countries at US$9.5 billion (Brookes and Barfoot, 2016).
Increased adoption of biotech drought tolerant maize in the US
Biotech DroughtGard™ tolerant maize, first planted in the US in 2013, increased more than 15-fold from 50,000 hectares in 2013 to 275,000 hectares in 2014 and 810,000 hectares in 2015, reflecting high farmer acceptance at 3-fold year-to-year between 2014 and 2015. The same event, MON 87460, was donated by Monsanto to the public-private partnership, Water Efficient Maize for Africa (WEMA) aimed at delivering biotech drought tolerant maize to selected countries in Africa by 2017. Biotech drought tolerance is an extremely important goal given that droughts will likely become more severe and more frequent, as climate change impacts crop productivity, agriculture and society. Notably, the conventional drought tolerant maize has been distributed in South Africa in 2014 which is hoped to facilitate acceptance of the biotech drought tolerant maize DroughtGard™ (MON 87460) which was approved for commercialization in June 2015, and expected to be available to farmers in 2017.
A selection of “new” biotech crops, several home-grown, were approved in 2015 and planned for commercialization in 2016 and beyond, in countries other than the US, which is covered earlier in this Executive Summary.
In Argentina, two home-grown products were approved – a drought tolerant soybean and a virus-resistant potato. In Brazil, approval was gained for cultivation of a 20% higher yielding home-grown eucalyptus, developed by FuturaGene/Suzano, plus commercialization of two home-grown crop products in 2016 – a virus resistant bean and a new herbicide tolerant soybean. In Myanmar, a new Bt cotton variety Ngwe-chi-9 was commercialized in 2015. In Canada, there was approval of a higher quality non-browning apple. Note, the important shift towards more food crops – current biotech food crops include white maize in South Africa, sugar beet and sweet corn in the US and Canada; papaya, squash, potato and apple in the US; papaya in China; and Bt eggplant in Bangladesh.
Stacked traits occupied 33% of the global 179.7 million hectares, up from 28% in 2014.
Stacked traits are favored by farmers in all countries for all crops. Stacked traits increased from 51.4 million hectares in 2014 to 58.5 million hectares in 2015 – an increase of 7.1 million hectares equivalent to a 14% increase. The substantial shift to stacked traits was largely due to an increase in Bt/HT soybean with 12.9 million hectares principally planted in Brazil, and to a lesser extent by its neighbors, Argentina, Paraguay and Uruguay. Stacked traits continued to be an important and growing feature of biotech crops – 14 countries planted biotech crops with two or more traits in 2015, of which 11 were developing countries. Vietnam planted a stacked biotech Bt/HT maize as its first biotech crop in 2015.
The 5 lead biotech developing countries in the three continents of the South: Brazil and Argentina in Latin America, India and China in Asia, and South Africa on the continent of Africa, grew almost half (48%) of global biotech crops and represent ~41% of world population.
The five lead developing countries in biotech crops in the three continents of the South are India and China in Asia, Brazil and Argentina in Latin America, and South Africa on the continent of Africa. They collectively grew 86.3 million hectares (48% of global) and together represent ~41% of the global population of 7.3 billion, which could reach ~11.0 billion, or more, by the turn of the century in 2100. Remarkably, the population in Africa alone could escalate from ~1.2 billion today (~16% of global) to a possible high of 4.4 billion (~39% of global) by the end of this century in 2100. On a hectarage basis, of the 28 countries that planted biotech crops in 2015, 87% of the hectarage was in the Americas, 11% in Asia, 2% in Africa and <1% in Europe.
Ten Latin American countries benefit from biotech crops.
It is noteworthy, that there are now 10 countries in Latin America which benefit from the extensive adoption of biotech crops. Listed in descending order of hectarage, they are Brazil, Argentina, Paraguay, Uruguay, Bolivia, Mexico, Colombia, Honduras, Chile, and Costa Rica, with Cuba planning to resume planting in two years pending availability of their home-grown maize hybrids.
Brazil, the global engine of growth for biotech crops is second only to the US in biotech crop hectarage.
In 2015, Brazil ranked second only to the USA in biotech crop hectarage in the world with 44.2 million hectares (up from 42.2 million in 2014); the increase in 2015 was 2 million hectares equivalent to a growth rate of 5%. For the last six years, Brazil was the engine of growth globally. In 2015, Brazil grew 25% (2% more than in 2014) of the global hectarage of 179.7 million hectares. In the long term, Brazil is expected to close the gap with the US which has an efficient and science-based approval system that facilitates fast adoption. In 2015, Brazil commercially planted, for the third year, the stacked soybean with insect resistance and herbicide tolerance on 11.9 million hectares, up substantially (five-fold increase) from 2.3 million hectares in 2013 and 5.2 million hectares in 2014. In Brazil, approval was gained by FuturaGene /Suzano for cultivation of a 20% higher-yielding home-grown biotech eucalyptus, plus commercialization of two home-grown crop products in 2016 – a virus resistant bean and a new herbicide tolerant soybean.
Canada decreased hectarage of biotech canola, whereas biotech national hectares in Australia increased due to biotech canola.
Canada retained its fifth place in world ranking of biotech crops with biotech crop hectarage of 11.0 million hectares compared with 11.6 million hectares in 2014 ‒ a ~5% decrease, largely due to a decrease in hectarage of total canola and driven by low canola prices. The decrease in canola hectares in 2015 is expected to reverse when prices of canola increase, and become more competitive versus other crops. Australia grew 658,000 hectares of biotech crops in 2015 compared to 542,000 hectares in 2014, a 21% increase. This comprises 214,000 hectares cotton, a 7% increase from 200,000 hectares in 2014; and 444,000 hectares biotech canola, a 30% increase from 342,000 hectares in 2014. Notably, biotech cotton adoption remains at ~100% of all cotton grown in Australia and ~99% of it featured the stacked traits (insect resistance and herbicide tolerance). Australia is providing global leadership in deployment of biotech cotton and insect resistance management with Bollgard® lll already field-tested in 2015 on ~30,000 hectares.
India sustains its biotech cotton hectarage and becomes #1 cotton producer in the world.
In a landmark development, India became the #1 cotton producer in the world, with much of the success attributed to Bt cotton. India continued to be the largest biotech cotton country in the world with 11.6 million hectares planted by 7.7 million small farmers with an adoption rate of 95%, similar to 2014. Brookes and Barfoot’s latest estimate indicated that India had enhanced farm income from Bt cotton by US$18.3 billion in the twelve-year period 2002 to 2014 and US$1.6 billion in 2014 alone.
Status of Bt cotton and virus resistant papaya in China
In 2015, China successfully planted ~3.7 million hectares of biotech cotton at an adoption rate of 96%, (up from 93% in 2014) of its 3.8 million total cotton hectarage. In addition, ~7,000 hectares of virus resistant papaya were planted in Guangdong, Hunan Island and Guangxi; plus ~543 hectares of Bt poplar. Despite China’s decreased total cotton hectarage, from 4.2 million hectares in 2014 to 3.8 million hectares, mainly due to lower prices and high stockpiles of cotton in China, biotech cotton adoption rate has increased from 93% in 2014 to 96% in 2015, and planted by an estimated ~6.6 million or more farmers. Virus resistant papaya plantings decreased from 8,475 hectares in 2014 to 7,000 hectares in 2015, due to over supply in 2014, but the adoption rate remained high at ~90%. In addition to farmers benefiting directly from biotech Bt cotton, there may be an additional 10 million secondary beneficiary farmers cultivating 22 million hectares of crops which are alternate hosts for cotton bollworm and benefit from decreased pest infestation due to the planting of Bt cotton. Thus, the actual total number of beneficiary farmers of biotech Bt cotton in China alone may well exceed 17 million. Economic gains at the farmer level from Bt cotton for the period 1997 to 2014 was US$17.5 billion and US$1.3 billion for 2014 alone.
Bt maize and Bt rice, offer significant potential benefits and have enormous implications for China, Asia, and the rest of the world in the near, mid and long term, because rice is the most important food crop and maize the most important feed crop in the world. China’s research and commercialization of Bt maize, herbicide tolerant maize and phytase maize as well as Bt rice, will be very important potential contributions to China and the global food and feed needs. Whereas, President Xi Jinping has endorsed the GM technology that is used in biotech soybean and maize imported by China in very large quantities (77 million tons of soybean and 3.3 million tons of maize in 2015), domestic production of these biotech crops has not been implemented to-date. It is noteworthy that at the same time that the US approved biotech potato in 2015, China, the largest producer of potatoes in the world (6 million hectares), announced its intention to double its potato hectarage and designated potato as its fourth food staple following rice, maize, and wheat.
The Chinese government has disbursed at least US$3 billion to research institutes and domestic companies to develop home-grown biotech seeds and discussions are underway to expedite approvals of pending biotech crops for cultivation. Domestic production of biotech maize would increase productivity and reduce China’s dependency on imports of increasing quantities of maize, most of which (more than 90%) are biotech. China consumes one-third of global soybean production and imports 65% of global soybean imports, over 90% of which is biotech. Some observers speculate that home-grown biotech maize (Bt or phytase maize) will be commercialized in the next three years, opening up an enormous potential market of 35 million hectares of maize. Thus, biotech crops could help China become less dependent on increasing imports of soybean and maize, over 90% of which are biotech. Bloomberg (November 2015) reported that President Xi Jinping has been urging China to support “strong research and innovation” on GM crops. His urging is consistent with the US$43 billion bid from ChemChina for Syngenta, which could have high potential impact on the timely adoption of biotech maize on up to 35 million hectares in China in the near-term. A successful bid would provide ChemChina with immediate access to a large portfolio of ready-made safety-tested commercial GM crop products that have been grown globally for many years.
Status in Africa
Despite some significant challenges, the African continent continued to make general progress on several fronts. A devastating drought in South Africa resulted in the country decreasing its intended biotech crop hectarage in 2015 by approximately 700,000 hectares from 3 million hectares to 2.3 million hectares – a massive 23% decrease. This underscores yet again the critical nature, and potentially life-threatening importance of drought in Africa and the impending new drought challenges exacerbated by climate change. Importantly, the drought tolerant maize (DroughtGard®) under the WEMA project has been approved for general release in South Africa, while the (DT) maize with insect control (Bt) will be launched as scheduled in 2017. Sudan increased Bt cotton hectarage by 30% to 120,000 hectares whilst political transition changes and fiber quality precluded a potentially higher hectarage than ~0.4 million hectares in Burkina Faso. An additional eight countries (Cameroon, Egypt, Ghana, Kenya, Malawi, Nigeria, Swaziland and Uganda) conducted field trials on priority African crops, the penultimate step prior to approval. The on-going trials focus on traits of high relevance to challenges facing Africa, including drought, nitrogen use efficiency, salt tolerance, nutritional enhancement, as well as resistance to tropical pests and diseases. Slow implementation of science-based and cost/time-effective regulatory systems is the major constraint to adoption. Responsible, rigorous but not onerous regulation is urgently needed to suit the needs of both public and private sector technology developers in ensuring smooth delivery of the much needed tool into the hands of African famers. Ultimately, sustained political goodwill and intense engagement with all sector players will be keys in unlocking the regulatory stalemate.
Five EU countries planted 116,870 hectares of biotech Bt maize. Spain was by far the largest adopter, planting 92% of the total Bt maize hectarage in the EU.
The same five EU countries (Spain, Portugal, Czechia, Slovakia and Romania) continued to plant 116,870 hectares of Bt maize, down 18% from the 143,016 hectares planted in 2014. Spain, which grew 92% of all biotech maize, led the EU with 107,749 hectares of Bt maize, down 18% from the 131,538 in 2014, with a 28% adoption rate compared with a 31% adoption in 2014. Bt maize hectarage decreased in all five EU countries. The decreases in Bt maize were associated with several factors, including less total hectares of maize planted in 2015, but also due to significant disincentives for farmers confronted with bureaucratic and onerous reporting of intended plantings of Bt maize. In October 2015, 19 of the 28 EU countries voted to opt out of growing biotech crops but importantly all five countries currently growing Bt maize voted to continue planting so that they can benefit from the significant advantages that biotech crops offer.
Status of approved events for biotech crops
As of November 15, 2015, a total of 40 countries (39 + EU – 28) have granted regulatory approvals to genetically modified crops for use as food and/or feed use or for environmental release since 1994. From these countries, 3,418 regulatory approvals have been issued by regulatory authorities across 26 GM crops (not including carnation, rose and petunia) and 363 GM events. The top five countries with the most number of regulatory approvals include Japan (214 approvals), U.S.A. (187 not including stacked events), Canada (161), Mexico (158), and South Korea (136). Maize still has the most number of approved events (142 in 29 countries), followed by cotton (56 events in 22 countries), potato (44 events in 11 countries), canola (32 events in 13 countries), and soybean (31 events in 28 countries). The herbicide-tolerant maize event NK603 (54 approvals in 26 countries + EU-28) has the most number of approvals followed by the herbicide-tolerant soybean event GTS 40-3-2 (52 approvals in 26 countries + EU-28), the insect-resistant maize MON810 (50 approvals in 25 countries + EU-28), and the insect-resistant maize Bt11 (50 approvals in 24 countries + EU-28). In December 8, 2015, the Supreme Court of the Philippines decided that the conduct of Bt eggplant field testing is permanently enjoined; the Department of Agriculture Administrative Order No. 08, series of 2002 is declared null and void; and, consequently, any application of contained use, field testing, propagation, and commercialization, and importation of genetically modified organisms is temporarily enjoined until a new administrative order is promulgated in accordance with the law.
Global value of biotech seed alone was ~US$15.3 billion in 2015
In 2015, the global market value of biotech crops, estimated by Cropnosis, was US$15.3 billion, (down marginally from US$15.7 billion in 2014); this represents 20% of the US$76.2 billion global crop protection market in 2014, and 34% of the ~US$45 billion global commercial seed market. The estimated global farm-gate revenues of the harvested commercial “end product” (the biotech grain and other harvested products) are more than ten times greater than the value of the biotech seed alone. A 2011 study estimated that the cost of discovery, development and authorization of a new biotech crop/trait was ~US$135 million. A report by Transparency Market Research for the period 2013-2019 indicated that, global agricultural biotechnology which was worth US$15.3 billion in 2012 is expected to be worth US$28.7 billion by 2019. The value is estimated to expand at a rate of 9.5% compounded annual growth rate (CAGR) from 2013 to 2019 due to the rising demand for higher crop yield, combined with diminishing amounts of arable land that will drive the transgenic application segment of the market.
The enormous challenge of feeding 9.7 billion in 2050
Feeding 9.7 billion people in 2050, and ~11.0 billion in 2100, is one of, if not THE most daunting challenges facing mankind during the remaining years of this century. Global population, which was only 1.7 billion at the turn of the century in 1900, is now 7.3 billion (July 2015) – the world has added approximately 1 billion people in the span of the last 12 years. It is expected to climb to 9.7 billion by 2050, and to 11 billion at the end of this century in 2100. Globally, 870 million people are currently chronically hungry and 2 billion are malnourished. The world may consume more grain than it produced in 2015. Rates of growth in crop productivity have declined subsequent to the significant contribution of the green revolutions of the 1960s for wheat and rice. It is now evident that conventional crop technology alone will not allow us to feed over 9 billion in 2050 and neither is biotechnology a panacea. An option being proposed by the global scientific community is a balanced, safe and sustainable approach, using the best of conventional crop technology (well adapted germplasm) and the best of biotechnology (appropriate GM and /non-GM traits) to achieve sustainable intensification of crop productivity on the 1.5 billion hectares of cropland globally. The returns on investments in agriculture are high and furthermore they directly impact on poverty alleviation, particularly on small resource-poor farmers and the rural landless dependent on agriculture, who represent the majority of the world’s poorest people.
Climate Change: Papal Encyclical and COP 21 in Paris
Pope Francis in his 2015 papal encyclical, ‘Laudato Si’, underscored the importance for everyone, in a coordinated effort, to implement the necessary strategies to address climate change and environmental destruction which will affect everyone, especially the vulnerable members of global society – the poor and the hungry. Efforts in the past by rich countries to help poor countries were determined not to be sufficient, hence there is an urgent global need to double and unify efforts.
The Pope’s concern was also appropriately addressed in a clarion call for action (not promises) during the 21st Session of the Conference of the Parties (COP21) to the UN Framework Convention on Climate Change (UNFCCC) held in Paris, France in December 2015. Importantly, for the first time ever, a legally binding agreement was signed by 195 countries to limit global warming to below 2oC, above which, global crop production will decline substantially, particularly the developing countries, which can least afford the losses due to abiotic-stresses (higher temperatures and droughts) and biotic-stresses (pests, weeds and diseases). It is very important to acknowledge that GM/biotech crops are already making a contribution to reduce the effects of increased stresses associated with climate change, as detailed in the next paragraph. Moreover, the potential of GM and the new biotech applications, such as CRISPR, is enormous for the future, when global population will reach 11 billion in 2100. The challenge for society is to adopt harmonized, science-based, appropriate and proportionate regulation, which is practical and not overly onerous, that will ensure timely deployment to farmers of improved crops that can increase productivity, and double food production.
Biotech crops contribution to Food Security, Sustainability, the Environment and Climate Change
The latest data for 1996 to 2014 showed that biotech crops contributed to Food Security, Sustainability and Climate Change by: increasing crop production valued at US$150 billion; providing a better environment, by saving 583.5 million kg a.i. of pesticides in 1996-2014; in 2014 alone reducing CO2 emissions by 27 billion kg, equivalent to taking 12 million cars off the road for one year; conserving biodiversity in the period 1996-2014 by saving 152 million hectares of land (Brookes and Barfoot, 2016); and helped alleviate poverty by helping up to 16.5 million small farmers, and their families totaling >65 million people, who are some of the poorest people in the world. Biotech crops can increase productivity and income significantly and hence, can serve as an engine of rural economic growth that can contribute to the alleviation of poverty for the world’s small and resource-poor farmers. Biotech crops can contribute to a “sustainable intensification” strategy favored by many Academies of Science worldwide, which allows productivity/production to be increased only on the current 1.5 billion hectares of global crop land, thereby saving forests and biodiversity. Biotech crops are essential but are not a panacea and adherence to good farming practices, such as rotations and resistance management for insects, pathogens and weeds, are a must for biotech crops as they are for conventional crops.
Regulation of biotech crops
Onerous regulation for transgenic biotech crops remains the principal constraint to adoption, which is particularly important for many developing countries, denied the opportunity of using biotech crops to address food, feed and fiber security. Unlike the onerous regulation that currently applies to transgenics, genome-edited products logically lend themselves for science-based, fit-for-purpose, proportionate and appropriate regulation. Opponents of GM crops and the new genome editing technologies such as CRISPR are opposed to science/evidence-based regulation and are demanding onerous regulation that is denying poor farmers in the developing countries, as well as Europe’s access to the technologies. By using these technologies, small poor farmers will be able to survive and contribute to the doubling of food production to meet the needs of a growing population which will reach 11 billion in 2100. Moreover, the opponents of GM crops and the biotech applications such as CRISPR are estimated to have a massive global budget which doubled from an estimated US$10 billion in 2011 to US$20 billion in 2014.
The encouraging outlook is that technology, in conjunction with conducive policies can double food production. However, the doubling of food production cannot be realized by society unless it ensures that regulation of GM and genome-edited derived crops is science/evidence-based, fit-for-purpose, and to the extent possible harmonized globally. Failure by global society to ensure timely and appropriate regulation on food production will have dire consequences. On the one hand the world will suffer because of inadequate food supplies, whilst on the other hand the power of science and technology to produce a safe, adequate and assured supply of food for all of mankind will be rejected because of the dominant ideological voices of the opponents of the new biotech technologies.
Global meta-analysis, confirms significant and multiple benefits
The meta-analysis conducted by Klumper and Qaim (2014) on 147 published biotech crop studies during the last 20 years, concluded that “on average, GM technology adoption has reduced chemical pesticide use by 37%, increased crop yields by 22%, and increased farmer profits by 68%. Yield gains and pesticide reductions are larger for insect-resistant crops than for herbicide-tolerant crops. Yield and profit gains are higher in developing countries than in developed countries.” These findings corroborate the findings of the annual global impact study by Brookes and Barfoot of PG Economics, annually referenced in the Annual ISAAA Briefs. Qaim (2015) presented a more thorough description of the impacts of current and possible future GM crop applications, and their substantial contribution to sustainable agricultural development and food security, in his recent book, Genetically Modified Crops and Agricultural Development. He concluded that continued opposition to technologies that were shown to be beneficial and safe entails unnecessary human suffering and environmental degradation.
Status of Golden Rice
WHO concluded that 190 to 250 million preschool children worldwide are affected by VAD annually. Golden Rice could prevent 1.3 to 2.5 million child deaths annually. At IRRI, the Golden Rice trait event E, has been bred into mega varieties, and confined field tests are in progress in the Philippines and a field trial has been approved in Bangladesh. The important mission of the Golden Rice project is to contribute to improving the health of millions of people suffering from micronutrient deficiency. Rice is the staple of 4 billion people in the South who collectively consume only 2,006,869 calories per day. This consumption is broken down by region, per day in: South Asia (1,130,648 calories), Southeast Asia (660,979 calories), Africa (125,124), Latin America (75,238), and Central Asia (14,880) for a total of 2,006,869 calories per day (HarvestPlus, Personal Communications). These are the regions where most Vitamin A Deficiency (VAD) and associated illnesses occur – these can be reduced if people are provided with Golden Rice, a biotech rice with beta carotene. Around 100 to 150 grams per day of the improved Golden Rice will provide more than half the needs of people suffering from vitamin A deficiency.
New Breeding Technologies (NBT): The critical role of utilizing evolving and promising new biotechnology applications, such as CRISPR, in crop improvement
Twenty years after the commercialization of biotech/GM crops developed through the use of Agrobacterium or particle bombardment, the scientific global community are again enthusiastic about the potential of a new crop biotechnology called “genome or gene editing”. There are different types of genome editing technologies, the most recent named CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat) is judged to be promising by many stakeholders. These new technologies allow the cutting of the DNA at a pre-determined location and the precise insertion of the mutation, or single nucleotide changes at an optimal location in the genome for maximum expression. Readers are referred to two essays on new breeding technologies and genome-edited applications in the collection of invitational essays in the companion document to the Brief on the ISAAA website. Experts in the field believe that potentially the “real power” of these new technologies is their ability to “edit” and modify single or multiple native plant genes (non-GM), coding for important traits such as drought and, generating useful improved crops that are not transgenic. Products already under development include all the major food and feed crops: canola (herbicide tolerance), maize (drought tolerance), wheat (disease resistance and hybrid technology), soybean (oil quality), rice (disease resistance), potato (improved storage qualities), tomato (fruit ripening), and peanuts (allergen-free). More complex traits, coded by multiple genes, like improved photosynthesis, are planned for the future, which may be closer than some people think. CRISPR earned Science’s 2015 “Breakthrough of the Year Laurels”. A runner-up in 2012 and 2013, the technology now revolutionizing genetic research and gene therapy “broke away from the pack, revealing its true power in a series of spectacular achievements,” opined Science correspondent John Travis in the December 18 issue.
Acknowledging that no technology, including genome editing, is a panacea or a silver bullet, many well-informed observers in the scientific community (gene therapy in medicine, where the technology was first developed, and crop improvement in agriculture) are of the view that genome editing offers a timely and unique set of significant comparative advantages over conventional and GM crops in four domains: precision – due to its ability to precisely control single or multiple genes resulting in products that do not differ from natural mutations; regulation – unlike the onerous regulation that currently applies to transgenics, genome-edited products logically lend themselves for science-based, fit-for-purpose, and proportionate regulation; speed – some products, for example, genome-edited derived potato, have been developed in only one year, compared with up to 10 years using conventional or GM technology; and cost – higher speed in improving crops and reduced regulation translates into significant overall savings. The average cost for developing a GM crop is US$135 million of which US$35 million is onerous regulation costs. The hope is that regulatory bodies worldwide will not require stringent regulation for genome edited crops and to the extent possible facilitate harmonization of regulations internationally. This augers well for the new genome-edited technologies which will allow more affordable, superior, state-of-the-art crops to be offered to producers and consumers.
To ISAAA’s knowledge, the first non-GM, genome-edited product, to be approved and commercialized is SU Canola™ developed by Cibus and grown on 10,000 acres (4,000 hectares) in the USA in 2015. Canada has also approved SU Canola™ for planting. Similar non-GM products are under development in many laboratories globally with a view to commercialization by farmers as early as five years from now in 2020. For example, DuPont has indicated that it already has CRISPR-derived maize and wheat plants growing in the greenhouse and is hoping to conduct the first field tests in 2016. Several countries − USA, Canada, Sweden and Argentina, have already considered regulation of simply mutated products through CRISPR and similar technologies, and concluded that they do not require to be deregulated under their respective national GM regulations. Dr. Jansson from Sweden has opined that “the decision of the Swedish Board of Agriculture is the only logical one” for their particular genome-edited products. Importantly, the determination of the need to regulate should be focused on the specific product and not the process.
Leading scientists from the global scientific community are of the view that international harmonization of science-based regulation of genome-edited crops is absolutely critical for plant breeding programs. This is because these programs are required to urgently increase global crop productivity, in order to achieve food security for 11 billion people in 2100, as well as mitigating the additional and formidable challenges, such as more frequent and more severe droughts posed by climate change. The EU and many other countries are expected to report their findings, positions and decisions on regulation of genome-edited technologies in the near term – these will be critical game-changing decisions with global implications for the role of science in food security, climate change, and the alleviation of hunger and poverty for almost one billion people in the developing countries.
To summarize, the unusual degree of interest and enthusiasm in genome editing is that, relative to other conventional and GM technologies, it is simple, swift, precise and affordable – features that make it a universally attractive development for most stakeholders. Genome editing can help solve the misery of the ~850 million poor people who are suffering from food insecurity in the developing countries, where one thousand people an hour die from hunger and malnutrition – a situation that is unacceptable in a just society. Norman Borlaug opined that you cannot build peace on empty stomachs, and that technology can contribute to food security and a better quality of life for millions of poor people – he was right – the right to adequate food is imperative, and biotechnology can help make it happen.
There are three domains that merit considerations:
Firstly, the high rates of adoption (90% to 100%) of current major biotech crops leave little room for expansion in mature markets in principal biotech crop countries. However, there is a significant potential for selected products such as biotech maize. For example, in Asia, there are about 60 million hectares of potential biotech maize, with 35 million hectares in China alone; there is a similar potential in Africa for up to 35 million hectares of biotech maize and for biotech cotton, in up to 10 African countries growing 100,000 hectares, or more, of cotton.
Secondly, the pipeline is full of new biotech crop products which could (subject to regulatory approval for planting and import) be available during the next 5 years or so ‒ a portfolio of over 85 potential products are listed in the full Brief. They include, the WEMA-derived biotech drought tolerant maize expected to be released in Africa in 2017, a broad range of new crops and traits including products with multiple modes of resistance to pests/diseases and tolerance to herbicides, as well as resistance to nematodes. Golden Rice is progressing with field testing in Asia. Crops for the poor, particularly in Africa, such as fortified bananas and pest resistant cowpea, look promising and institutionally, public-private partnerships (PPP) have been relatively successful in developing and delivering approved products to farmers ‒ four PPP case studies, featuring a broad range of different biotech crops and traits in all three continents of the South, are presented in the Appendix of the full Brief.
Thirdly, the advent of genome-edited crops may be, by far, the most important development identified by today’s scientific community. A recent and promising application is the powerful technology named CRISPR. Many well-informed observers in the scientific community are of the view that genome editing offers a timely and powerful unique set of significant advantages over conventional and GM crops in four domains: precision, speed, cost and regulation – unlike the onerous regulation that currently applies to transgenics; genome-edited products logically lend themselves for science-based, fit-for-purpose, and proportionate regulation. Progress with the latter would be an enormous advantage. For more details the reader is referred to two essays in the companion document to Brief 51 on the ISAAA website (to celebrate the 20th anniversary of the commercialization of biotech crops) which describe the evolution of crop improvement technology, particularly the role of the new breeding technologies (NBT). It includes a proposed forward-looking strategy of using the troika of transgenes, genome editing and microbes (the use of plant microbiomes as a new source of additional genes to modify plant traits) to increase crop productivity which in turn can contribute to the noble goal of food security and the alleviation of hunger and poverty.
The Way Forward
The way forward is to work together – collaboration – between the North and the South, East and West, Public and Private Partnerships (PPP), using both conventional (well-adapted germplasm) and biotechnology applications (enhanced beneficial traits). In reviewing crop technology transfer projects over the last two decades, the progress and promise of public-private sector partnerships (PPP) is striking. PPP projects offer flexibility and have been successful under a very broad range of circumstances. Importantly, PPP offer advantages that increase the probability of delivering an approved biotech crop product at the farmer level within a reasonable time frame. Four PPP case studies/projects, selected and reviewed by ISAAA illustrate the range of diversity in the four model PPP projects: Bt brinjal (eggplant) in Bangladesh, herbicide tolerant soybean in Brazil, drought tolerant sugarcane in Indonesia, and the WEMA project for drought tolerance in maize in selected countries in Africa. For the convenience of readers, short updated descriptions of each of the four case studies, are summarized in the Appendix of Brief 51-2015.
Norman Borlaug’s Legacy and Advocacy of Crop Biotechnology
It is fitting and timely to close this celebratory 20th Anniversary ISAAA Brief for 2015, by chronicling the counsel of the late 1970 Nobel Peace Laureate, Norman Borlaug, on biotechnology including GM crops. Norman Borlaug, who saved a billion people from hunger, was awarded the Nobel Peace Prize for the impact of his semi-dwarf wheat technology on the alleviation of hunger and poverty. Norman Borlaug was also the founding patron of ISAAA, and the greatest advocate for biotechnology and biotech/GM crops worldwide.
Below is a memorable Norman Borlaug quote, in which he calls for courage from our leaders, (both scientific and political) to support crop biotechnology which can contribute to global food security and a more peaceful world. It is noteworthy that the quote is from the man who knew more than anyone about feeding the world because he had “done it” during the green revolution of the 1960s and understood the essence of the proverb – reading is learning, seeing is believing, but doing is knowing – knowledge. This Brief seeks to share knowledge freely about all aspects of biotech crops whilst respecting the rights of readers to make their own informed-decisions about crop biotechnology.
Norman Borlaug Quote:
“What we need is courage by the leaders of those countries where farmers still have no choice but to use older and less effective methods. The Green Revolution and now plant biotechnology are helping meet the growing demand for food production, while preserving our environment for future generations” (ISAAA, 2009).
Beijing (April 13, 2016) – Today, the International Service for the Acquisition of Agri-Biotech Applications (ISAAA) released its annual report detailing the adoption of biotech crops, “20th Anniversary of the Global Commercialization of Biotech Crops (1996-2015) and Biotech Crop Highlights in 2015,” showcasing the global increase in biotech hectarage from 1.7 million hectares in 1996 to 179.7 million hectares in 2015. This 100-fold increase in just 20 years makes biotechnology the fastest adopted crop technology in recent times, reflecting farmer satisfaction with biotech crops.
Since 1996, 2 billon hectares of arable land – a massive area more than twice the landmass of China or the United States – have been planted with biotech crops. Additionally, it is estimated that farmers in up to 28 countries have reaped more than US$150 billion in benefits from biotech crops since 1996. This has helped alleviate poverty for up to 16.5 million small farmers and their families annually totaling about 65 million people, who are some of the poorest people in the world.
“More farmers are planting biotech crops in developing countries precisely because biotech crops are a rigorously-tested option for improving crop yields,” said Clive James, founder and emeritus chair of ISAAA, who has authored the ISAAA report for the past two decades. “Despite claims from opponents that biotechnology only benefits farmers in industrialized countries, the continued adoption of the technology in developing countries disproves that” James added.
For the fourth consecutive year, developing countries planted more biotech crops (14.5 million hectares) than industrialized countries. In 2015, Latin American, Asian and African farmers grew biotech crops on 54 percent of global biotech hectarage (97.1 million hectares of 179.7 million biotech hectares) and of the 28 countries that planted biotech crops, 20 were developing nations. Annually, up to 18 million farmers, 90 percent of whom were small, resource-poor growers in developing countries, benefited from planting biotech crops from 1996 to 2015.
“China is just one example of biotechnology’s benefits for farmers in developing countries. Between 1997 and 2014, biotech cotton varieties brought an estimated $17.5 billion worth of benefits to Chinese cotton farmers, and they realized $1.3 billion in 2014 alone,” explained ISAAA Global Coordinator, Randy Hautea.
Also in 2015, India became the leading cotton producer in the world with much of its growth attributed to biotech Bt cotton. India is the largest biotech cotton country in the world with 11.6 million hectares planted in 2015 by 7.7 million small farmers. In 2014 and 2015, an impressive 95 percent of India’s cotton crop was planted with biotech seed; China’s adoption in 2015 was 96 percent.
“Farmers, who are traditionally risk-averse, recognize the value of biotech crops, which offer benefits to farmers and consumers alike, including drought tolerance, insect and disease resistance, herbicide tolerance, and increased nutrition and food quality,” Hautea added. “Moreover, biotech crops contribute to more sustainable crop production systems that address concerns regarding climate change and global food security.”
Following a remarkable run of 19 years of consecutive growth from 1996 to 2014, with 12 years of double-digit growth, the global hectarage of biotech crops peaked at 181.5 million hectares in 2014, compared with 179.7 million hectares in 2015, equivalent to a net marginal decrease of 1 percent. This change is principally due to an overall decrease in total crop hectarage, associated with low prices for commodity crops in 2015. ISAAA anticipates that total crop hectarage will increase when crop prices improve. For example, Canada has projected that canola hectarage in 2016 will revert to the higher level of 2014. Other factors affecting biotech hectarage in 2015 include the devastating drought in South Africa, which led to a massive 23 percent decrease of 700,000 hectares in intended plantings in 2015. The drought in eastern and southern Africa in 2015/2016 puts up to 15 to 20 million poor people at risk for food insecurity and compels South Africa, usually a maize exporter, to rely on maize imports.
Additional highlights from ISAAA’s 2015 report include:
Looking ahead to the future of biotechnology in agriculture, ISAAA has identified three key opportunities to realize continued growth in adoption of biotech crops, which are as follows:
For more information or the executive summary of the report, visit www.isaaa.org.